Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
NCT ID: NCT02040883
Last Updated: 2014-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2014-02-28
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
NCT03790085
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
NCT04959201
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
NCT04528095
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
NCT04076371
The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia
NCT02021201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Study Group
Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Tandospirone
Tandospirone，30mg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Tandospirone
Tandospirone，30mg per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-65 years (including 18 and 65), male or female.
* Treated with a stable dose of an AAPD for at least three months.
* Informed consent was obtained (if the patient is in the acute phase of schizophrenia, does not have the capacity, their guardians need sign informed consent).
* PANSS negative score ≤60.
Exclusion Criteria
* Taking a mood stabilizer, antidepressants, anticholinergic or anxiolytic drugs, and other drugs improve cognitive function;
* Suicidal tendencies;
* Have severe or unstable heart, liver, kidney, endocrine, blood and other medical disease patients
* Clinically significant ECG or laboratory abnormalities were
* Glaucoma and epilepsy;
* Unsupervised or unable to take prescribed medication;
* History of alcohol and drug abuse;
* Allergic;
* Pregnant or lactating woman;
* Patients participate in other clinical trials during a month;
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qingyun Yin
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qingyun Yin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qingyun Yin
Role: PRINCIPAL_INVESTIGATOR
Guangzhou Psychiatric Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Psychiatric Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSPC-SED20130516
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.